Michael P. Bailey serves as president and chief executive officer for AVEO Oncology (an LG Chem company) and is a member of AVEO’s board of directors.  Michael brings more than 30 years of experience in the pharmaceutical industry to the company. Before the acquisition of AVEO by LG Chem in January of 2023, Mr. Bailey was named president and chief executive officer of AVEO Oncology in January 2015, prior to that appointment, Mr. Bailey served as AVEO’s chief business officer from 2013 to 2015 and its chief commercial officer from 2010 to 2013. Mr. Bailey joined AVEO from Synta (now Madrigal Pharmaceuticals), where he served as senior vice president, business development, and chief commercial officer since 2008. Prior to joining Synta, Mr. Bailey led ImClone Systems’ (now Eli Lilly) Worldwide Commercial Organization. During his nine-year tenure at ImClone Systems, he was responsible for commercial aspects of the planning and launch of ERBITUX® (cetuximab) across multiple oncology indications, as well as new product planning for the ImClone Systems development portfolio, which included CYRAMZA® (ramucirumab) and necitumumab. In addition, Mr. Bailey was a key member of the strategic leadership committees for ImClone and its North American and worldwide partnerships. Prior to joining ImClone Systems, Mr. Bailey managed the cardiovascular development portfolio at Genentech, Inc., and was a key member of their global commercial partnership teams. Mr. Bailey started his career in the pharmaceutical industry as part of SmithKline Beecham’s Executive MBA Marketing Development Program, where he held a variety of commercial roles, including sales, strategic planning, and product management. Mr. Bailey received a B.S. in psychology from St. Lawrence University and an M.B.A. in international marketing from the Mendoza College of Business at University of Notre Dame.

Currently, Mr. Bailey also serves as chairman of the board of directors of IMV Inc., a clinical-stage biopharmaceutical company.